肠道功能障碍标志物无法解释HIV相关结核中利福平生物利用度低
该前瞻性队列研究在博茨瓦纳哈博罗内纳入HIV/TB患者,在ART启动前后各进行一次密集采样药代动力学访视,用非线性混合效应模型检验肠道损伤、微生物易位和系统性免疫激活标志物是否与利福平生物利用度变异相关。结果显示这些标志物均无显著协变量效应,低利福平暴露在ART前占40%、ART后占46%,提示需治疗药物监测。
要点
- 肠道损伤、微生物易位和免疫激活标志物未显著影响利福平生物利用度。
- ART启动前40%、启动后46%的HIV/TB患者存在低利福平暴露。
- HIV/TB患者低利福平浓度风险难以预先识别,支持治疗药物监测。
核心结论
- 肠道损伤、微生物易位和系统性免疫激活标志物未能解释HIV/TB患者利福平生物利用度的变异。
研究设计与样本
- 在博茨瓦纳哈博罗内开展的前瞻性队列药代动力学研究,首次访视纳入40例HIV/TB患者,ART启动后第二次访视有24例返回。
主要发现
- 以最大血清浓度定义的低利福平暴露在ART启动前见于40%患者,ART启动后见于46%患者。
- 非线性混合效应模型未观察到肠道损伤、微生物易位或免疫激活标志物对利福平生物利用度有显著协变量效应。
关键数值与推荐
- 低利福平暴露定义为最大血清浓度偏低,ART前发生率为40%,ART后为46%。
临床怎么用
- HIV/TB患者低利福平浓度风险难以预先识别,支持在HIV/TB治疗期间进行治疗药物监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rifampicin is the key drug responsible for sterilizing activities in the first-line TB treatment regimen. Damage to the gut during acute and chronic HIV infection may inhibit drug absorptive capacity. We sought to test the hypothesis that markers of intestinal damage, bacterial translocation and systemic immune activation would relate to rifampicin bioavailability among HIV/TB patients. PATIENTS AND METHODS: We conducted a prospective cohort study of rifampicin pharmacokinetics in HIV/TB patients in Gaborone, Botswana. We performed two intensively sampled pharmacokinetic visits, before and after ART initiation. Non-linear mixed-effects modelling was performed to determine whether variability in markers of gut damage, microbial translocation or systemic immune activation contributed to variability in rifampicin bioavailability before and after the initiation of ART. RESULTS: We enrolled 40 HIV/TB patients in the first pharmacokinetic visit and 24 patients returned for the second pharmacokinetic visit after initiating ART. Low rifampicin exposure, as defined by the maximum serum concentration, was observed in 40% of patients prior to initiating ART and 46% of patients after initiating ART. In the non-linear mixed-effects model, we did not observe significant covariate effects of markers of gut damage, microbial translocation or immune activation on rifampicin bioavailability before and after ART initiation. DISCUSSION: Markers of intestinal damage, microbial translocation and systemic immune activation did not explain variability in rifampicin bioavailability. The a priori identification of HIV/TB patients at risk for low rifampicin concentrations remains a challenge, supporting a role for therapeutic drug monitoring during HIV/TB therapy.
引用
- Vinnard C, Ravimohan S, Tamuhla N, et al. Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB. J Antimicrob Chemother. 2017. PMID: 28472448. doi:10.1093/jac/dkx111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。